Cationic Peptide-Polymer Composite for Localized Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoarthritis, such as NSAIDs, opioids, steroid injectables, hyaluronic acid injectables, and knee replacement surgery, offer inadequate and short-lasting pain relief with significant side effects, and there is a need for long-lasting, safe modulation of nerve and muscle cell activity for conditions like pain, cardiac arrhythmias, and antimicrobial applications.
Innovation Solution
A peptide drug comprising a cationic peptide or amino acid monomer covalently bound to or mixed with a polymer, specifically a biocompatible polymer like hyaluronic acid, which reduces ion flow into excitable cells, providing long-lasting pain relief and antimicrobial effects through local administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If current treatments (NSAIDs, opioids, steroid injectables) are used for osteoarthritis pain relief, then pain management is achieved, but side effects increase and duration of action is short
Solution Approach 1:
The patent combines cationic peptides with polymers to create a composite therapeutic agent. The cationic peptide provides the active pharmacological effect for pain relief, while the polymer carrier provides sustained release and reduces toxicity. This composite approach extends the duration of action compared to conventional single-agent treatments while reducing harmful side effects through the buffering effect of the polymer.
Solution Approach 2:
The polymer acts as an intermediary carrier between the cationic peptide and the target tissue. It facilitates the delivery of the peptide to the site of action while controlling its release rate. The polymer intermediate protects the peptide from rapid degradation and distributes it over an extended period, thereby reducing peak concentrations and associated side effects while maintaining effective pain relief duration.
2Duration of action of moving object
If steroid injectables are used for pain relief, then pain management is achieved, but the effect lasts only 2-4 weeks and cartilage is destroyed
Solution Approach 1:
The cationic peptide-polymer composite is designed to be a temporary, degradable therapeutic agent. The polymer matrix is selected to be biodegradable, allowing the system to dissolve and clear from the body after delivering its therapeutic effect. This approach provides sustained pain relief without the need for repeated injections that would accumulate cartilage damage, as the therapy is administered less frequently due to its extended duration of action.
Solution Approach 2:
The patent modifies the pharmacokinetic parameters of the cationic peptide by conjugating it to a polymer with specific degradation characteristics. This changes the release rate and duration of action from hours to weeks or months. The polymer's degradation products are non-toxic and metabolizable, avoiding the cartilage destruction associated with steroid repeat injections while providing longer-lasting pain relief.
3Ease of operation
If hyaluronic acid injectables are used, then joint lubrication is improved, but pain relief is mild and efficacy is insufficient
Solution Approach 1:
The patent merges the lubricating properties of hyaluronic acid with the potent pain-relieving activity of cationic peptides. The composite formulation combines these two functional components in a single injectable preparation, thereby achieving both improved joint lubrication and reliable pain relief, overcoming the limitation of hyaluronic acid alone which provides only mild pain relief.
4Object-affected harmful factors
If knee replacement surgery is performed, then pain is eliminated, but it is expensive, invasive, and has high failure rate
Solution Approach 1:
The cationic peptide-polymer composite provides a non-surgical preliminary treatment that addresses pain and joint function before knee replacement becomes necessary. By extending the duration of action and reducing the frequency of interventions needed, this therapy can delay or prevent the need for surgery in many patients, avoiding the invasiveness, cost, and risks associated with knee replacement while effectively managing pain and improving quality of life.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide drug effectively reduces pain and muscle activity, offers antimicrobial properties, and provides a safer, longer-lasting solution compared to existing treatments by reducing toxicity and improving patient compliance.
Implementation Method 1
A peptide drug comprising a cationic peptide or amino acid monomer covalently bound to or mixed with a polymer, specifically a biocompatible polymer like hyaluronic acid, which reduces ion flow into excitable cells
Implementation Method 2
The positively charged cationic peptide is attracted to the negatively charged carboxylate groups in ion-channel openings on a nerve surface. In clinical use, the peptide drug or gel may be injected into the target area of the nerve and may act to block the sodium ion channels of the nerve cell, thereby preventing the entry of sodium ions into the intracellular space
Data Source
AI summary
The invention relates to a peptide drug for use as a localized antimicrobial agent and/or in the localised modulation of nerve cell activity, cardiomyocyte or muscle cell electrical activity in a subject, wherein the peptide drug comprises a polymer in a carrier, and further comprising: i) a plurality of cationic peptides, or an amino acid monomer thereof, covalently bound to the polymer; and/or ii) a plurality of cationic peptides, or an amino acid monomer thereof, mixed with the polymer. The invention further relates to the use of CARPs for use in the localised modulation of nerve cell activity, cardiomyocyte or muscle cell electrical activity in a subject. The invention further relates to modulation of chondrocyte function.